-
The world's first CAR-T cell therapy for inert lymphoma (iNHL).
Time of Update: 2021-02-28
The ZUMA-5 study was conducted in adult patients with R/R iNHL who had previously received at least two therapies, and interim analysis data showed that 93 percent of patients were in remission and 80 percent were fully relieved (CR) after a single injection of Yescarta.
-
The United States has approved Lynparza's treatment of HRD-positive advanced ovarian cancer
Time of Update: 2021-02-28
olaparib, which includes AstraZeneta and Merca East, has been approved in the United States as a first-line maintenance treatment, using beva monoantigen to treat HRD-positive advanced ovarian cancer.
-
Xinda Bio and Sanoki have reached a clinical partnership to develop Xindili monoantigen combination therapy
Time of Update: 2021-02-24
SNG1005 is a compound of yew alcohol molecules and amino acids short peptides imported from abroad, the product has completed several Phase II clinical trials in the United States, its Phase III clinical program has been approved by the U.S. Food and Drug Administration (FDA), Sanoki Pharmaceuticals has the right to develop and commercialize in Greater China.
-
The FDA has awarded Aeglea's lead therapy, pegzilarginase, a breakthrough drug
Time of Update: 2021-02-24
The FDA granted pegzilarginase BTD based on phase I/II studies conducted in ARG1-D patients and data from ongoing Phase II open label extension studies.
Data from the Phase I/II Study and Phase II Open Label Extension Study evaluating the treatment of PATIENT patients with ARG1-D show clinical improvement and a continued decline in plasma arginine.
-
AZ's Breztri scored in the COPD trial, adding a place to GSK's triple-combined battle
Time of Update: 2021-02-24
Related: analysis: AstraZeneta's Fasenra offers two-year benefits to people with severe asthma Meanwhile, AstraZeneta can rest assured that it will use other breathing drugs to boost GlaxoSmithKline while waiting for the triple-combination to catch up.
-
Bayer received FDA approval for Gadavist
Time of Update: 2021-02-24
Cardiac magnetic resonance imaging is a non-invasive imaging technique for non-invasive assessment of cardiovascular system function and structure, and the approval is to enable "medical professionals to use proven non-invasive methods to evaluate their patients" iconic world's most common form of heart disease," said Daniel Berman, director of cardiac imaging and nuclear cardiology at the Cedars-Sinai Heart Institute.
-
Takeda Arunbrig's first-line treatment of NSCLC is positive
Time of Update: 2021-02-24
For more than 2 years of follow-up, Alunbrig, a first-line therapy, reduced the risk of disease progression or death by 57% compared to the common generation of APK inhibitors.
-
FDA approves first new drug to treat patients with rare lung disease
Time of Update: 2021-02-24
The U.S. Food and Drug Administration today approved Ofev capsules to slow the decline in lung function in patients with interstitiotic pulmonary disease associated with systemic sclerosis or sclerosis, known as SSc-ILD.
-
AstraZenega's diabetes drug Farxiga reduces the risk of heart failure
Time of Update: 2021-02-24
“ Through the DAPA-HF trial, Farxiga became the first of its kind to demonstrate efficacy and safety data for treating patients with heart failure, whether or not they have type 2 diabetes, based on standard care," said Mene Pangalos, Executive Vice President of Research and Development at AstraZeneca Biopharmaceuticals.
-
Genfit's double agonist was awarded orphan drug status by the FDA and EMA
Time of Update: 2021-02-24
April 2019, the FDA also awarded Elafibranor Breakthrough Drug Qualification (BTD) for the treatment of adult PBC patients who did not respond well to UDCA.
Genfit plans to launch Phase III clinical studies in 2019 to further evaluate the efficacy and safety of elafibranor's treatment of PBC.
-
The U.S. Food and Drug Administration approved Nucara
Time of Update: 2021-02-24
(Mepoli monoanti) has been approved by the U.S. Food and Drug Administration (FDA) for use in children under the age of 6 with severe eosinophilic asthma.
This approval (40 mg dose of subsurfic injection) extends the current adaptation of Nucara in the United States to patients between the ages of 6 and 11.
-
Pfizer's biosimilar Rituxan has been approved by the FDA
Time of Update: 2021-02-24
“ Lytoxi monoantigen, which was initially approved by the FDA as one of the first monoclonal antibody (mAb) cancer treatments, represents significant progression and is the only available option for oncologists and their patients for a period of time," said Dr. Jeff Sharman, Director of Hematology Research Medicine at oncology in the United States.
-
Independent research and development of new anti-cancer drugs in the United States was approved for market
Time of Update: 2021-02-24
"This indicates that the research of innovative new drugs in our country has entered a fast track or a new platform, or even a new period of development." Zhu Jun said that most of the once-effective anti-cancer drugs were developed by foreign pharmaceutical companies and marketed abroad for many years before entering China, causing many patients to lose the best treatment time while waiting.
-
Mallinckrodt stopped the risk of pneumonia in the middle of the Acthar trial
Time of Update: 2021-02-24
Mallinckrodt announced that it would permanently discontinue Acthar's Phase IIb study, which aims to assess the efficacy and safety of Acthar Gel as a research treatment for amyotrophic lateral sclerosis (ALS).
Als is an aggressive neurodegenerative disease that affects motor neuron cells in the brain and spinal cord.
-
FDA approves new antimicrobial drugs to treat complex urinary tract infections
Time of Update: 2021-02-24
The U.S. Food and Drug Administration recently approved cefiderocol, an antimicrobial drug used to treat patients 18 years of age or older with complex urinary tract infections (cUTI), including kidney infections caused by susceptible Gloran-negative microorganisms, who have limited or no other treatment options.
-
FDA approves new treatments for complex urinary tract and complex celiac infections
Time of Update: 2021-02-24
The U.S. Food and Drug Administration has approved Recarbrio (aamine pernam, sestatins, and relebactam), an antibacterial drug product used to treat adult patients with complex urinary tract infections (cUTI) and intracarosis infections (cIAI).
-
Synthesis of the metal anticancer ru-rhein in tumor tissue
Time of Update: 2021-02-24
recently published in the National Science Review, In the NSR article, researchers at Nanjing Normal University and Nanjing University used the "bio orthosis catalytic lethality" strategy to develop a highly active tumor-targeted metal drug, Ru-rhein, a copper species with high concentrations in tumor tissue that can act as a catalyst to turn non-toxic premeditations Ru-N and rhein-alkyne into cytotoxic Ru-rhein, Ru-rhein-targeted tumor mitochondrials, and induced autophagy.
-
Puma Biotech Licensing Partners are market-licensed by Nerlynx
Time of Update: 2021-02-24
Puma Biotechnology corporation announced that the Argentine Medicines, Food and Medical Devices Authority (ANMAT) has approved Nerlynx (neranib) to extend complementary treatment for adult patients w
-
The stone drug Malay acid L-Achloride tablets are fully approved by the FDA
Time of Update: 2021-02-24
In the meantime, Shi medicine experienced a total of up to 5 years of clinical, 10 months of standard review time, and finally Xuanning's clinical data, fully recognized by the FDA, and no additional clinical trials are required.
-
China launches innovative drug for Alzheimer's disease
Time of Update: 2021-02-24
Shanghai Green Valley Pharmaceutical Co., Ltd. announced that China's original treatment of mild to moderate Alzheimer's disease new drug Ganlut sodium capsule (nine phase one) officially listed in China.
